CEO Newsletter 3, 2021
”Retreading old footsteps has never been a driving force for Fluicell” In the third issue of the CEO…
Fluicell launches Biozone 6
We are launching Biozone 6, Fluicell’s new innovation for single-cell pharmacology that lets you perform drug testing and…
15
Mar
2021
Biopixlar advances: Towards printing heart cells
Biopixlar’s microfluidic technology is ideal for printing even the most sensitive cell types. Using cells received from Dr….
12
Mar
2021
Fluicell in Di Hållbart Näringsliv
“Building human tissues cell by cell”. In an interview with Di Hållbart Näringsliv, Fluicell’s CEO Victoire Viannay talks…
09
Mar
2021
Biopixlar in 3D bioprinting eBook
“Biopixlar is a high-resolution bioprinting platform that uses a proprietary molecular cell-binding process and open volume microfluidics technology…
04
Mar
2021
Biozone 6™ launches March 15
Biozone 6™ is a new concept for direct single-cell pharmacology from Fluicell that lets users generate dose-response curves…
01
Mar
2021
CEO Newsletter 2, 2021
“2020 was a challenging but very successful year for Fluicell. In 2021, it is time to really pick…
24
Feb
2021
Origin of Life Webinar
How did the first life on earth emerge? The one who is asking this difficult question is Professor…
17
Feb
2021
Fluicell welcomes Andreas Svanström
I find biology very fascinating in its own diverse complexity and in the way it presents creative solutions…
16
Feb
2021